Membrane Proteins

Name
Membrane Proteins
Accession Number
DBCAT000031
Description

Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.

Drugs
DrugDrug Description
EtanerceptA protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.
Gramicidin DA bactericidal antibiotic used in the treatment of dermatological and ophthalmic infections.
EnfuvirtideAn HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals.
ColistinA polymyxin antibiotic used to treat bacterial infections caused by susceptible Gram negative bacteria.
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
TifuvirtideInvestigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
TisagenlecleucelA CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.
TG4010Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
TecemotideTecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
IsoxaflutoleBalance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
ColistimethateAn antibiotic indicated for treatment of infections caused by susceptible strains of certain gram-negative bacilli. It is particularly useful for targeting sensitive strains of Pseudomonas aeruginosa.
DirucotideFor the treatment of multiple sclerosis (MS).
TopsalysinInvestigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.
RomiplostimA fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
Nelipepimut-SInvestigated for use/treatment in prostate cancer and breast cancer.
OnerceptInvestigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
AMGN-0007Investigated for use/treatment in osteoporosis and bone metastases.
OmigananInvestigated for use/treatment in bacterial infection and rosacea.
PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
Bordetella pertussis pertactin antigenBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis .
LuspaterceptAn erythroid maturation agent used to treat anemia secondary to beta thalassemia, myelodysplastic syndromes, and neoplasms.
TiplimotideTiplimotide has been used in trials studying the treatment of Multiple Sclerosis.
DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
Recombinant CD40-ligandRecombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
AsunerceptAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
Cystic fibrosis transmembrane conductance regulatorCystic fibrosis transmembrane conductance regulator is under investigation in clinical trial NCT00004806 (Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis).
ALT-801ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
Brexucabtagene autoleucelA modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ζ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma.
IsegananIseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).
VEGFR2-169VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)).
PexigananPexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers).
Pam2csk4Not Available
VasomeraNot Available
Idecabtagene vicleucelAn autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
ReltecimodReltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
Myelin basic proteinNot Annotated
GI-6207Not Annotated
BatoclimabBatoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP).
Eftilagimod alfaEftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).
CDX-1135CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and...
P-113DFor the potential treatment of cystic fibrosis and bacterial infections.
GP-100 antigenGP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).
EDI-200EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
CHF5633CHF5633 is a fully synthetic pulmonary surfactant preparation comprising DPPC (dipalmitoylphosphatidylcholine), POPG Na (palmitoyl‐oleoyl‐phosphatidylglycerol sodium), a synthetic SP-C analogue, and a synthetic SP-B analogue.
LixisenatideA GLP-1 receptor agonist used for the management of type 2 diabetes mellitus.
TirzepatideA dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise.
Drugs & Drug Targets
DrugTargetType
EtanerceptTumor necrosis factortarget
EtanerceptLymphotoxin-alphatarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
EtanerceptComplement component 1q (C1q)target
Gramicidin DP-glycoprotein 1transporter
EnfuvirtideEnvelope glycoproteintarget
EnfuvirtideCytochrome P450 2C19enzyme
EnfuvirtideCytochrome P450 2E1enzyme
ColistinBacterial outer membranetarget
TifuvirtidePlasma serine protease inhibitortarget
TisagenlecleucelB-lymphocyte antigen CD19target
TG4010Mucin-1target
TG4010Interleukin-2target
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
ColistimethateBacterial outer membranetarget
RomiplostimThrombopoietin receptortarget
Thrombomodulin AlfaCoagulation factor Vtarget
Thrombomodulin AlfaProthrombintarget
PRO-542Free fatty acid receptor 4target
PegdinetanibVascular endothelial growth factor receptor 2target
Nelipepimut-SHLA class I histocompatibility antigen, A-2 alpha chaintarget
Nelipepimut-SHLA class I histocompatibility antigen, A-3 alpha chaintarget
OnerceptTumor necrosis factortarget
AMGN-0007Tumor necrosis factor ligand superfamily member 11target
Brexucabtagene autoleucelB-lymphocyte antigen CD19target
Pam2csk4Toll-like receptor 6target
Pam2csk4Toll-like receptor 2target
Idecabtagene vicleucelTumor necrosis factor receptor superfamily member 17target
LixisenatideGlucagon-like peptide 1 receptortarget
TirzepatideGlucagon-like peptide 1 receptortarget
TirzepatideGastric inhibitory polypeptidetarget
TirzepatideSerum albumincarrier